BACKGROUND: Radiation therapy is one of many treatment options for patients with prostate cancer. PURPOSE: To update findings on the clinical and biochemical outcomes of radiation therapies for localized prostate cancer. DATA SOURCES: MEDLINE (2007 through March 2011) and the Cochrane Central Register of Controlled Trials (2007 through March 2011). STUDY SELECTION: Published English-language comparative studies involving adults with localized prostate cancer who either had first-line radiation therapy or received no initial treatment. DATA EXTRACTION: 6 researchers extracted information on study design, potential bias, sample characteristics, interventions, and outcomes and rated the strength of overall evidence. Data for each study were extracted by 1 reviewer and confirmed by another. DATA SYNTHESIS: 75 studies (10 randomized, controlled trials [RCTs] and 65 nonrandomized studies) met the inclusion criteria. No RCTs compared radiation therapy with no treatment or no initial treatment. Among the 10 RCTs, 2 compared combinations of radiation therapies, 7 compared doses and fraction sizes of external-beam radiation therapy (EBRT), and 1 compared forms of low-dose rate radiation therapy. Heterogeneous outcomes were analyzed. Overall, moderate-strength evidence consistently showed that a higher EBRT dose was associated with increased rates of long-term biochemical control compared with lower EBRT dose. The body of evidence was rated as insufficient for all other comparisons. LIMITATIONS: Studies inconsistently defined and reported outcomes. Much of the available evidence comes from observational studies with treatment selection biases. CONCLUSION: A lack of high-quality comparative evidence precludes conclusions about the efficacy of radiation treatments compared with no treatments for localized prostate cancer. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
BACKGROUND: Radiation therapy is one of many treatment options for patients with prostate cancer. PURPOSE: To update findings on the clinical and biochemical outcomes of radiation therapies for localized prostate cancer. DATA SOURCES: MEDLINE (2007 through March 2011) and the Cochrane Central Register of Controlled Trials (2007 through March 2011). STUDY SELECTION: Published English-language comparative studies involving adults with localized prostate cancer who either had first-line radiation therapy or received no initial treatment. DATA EXTRACTION: 6 researchers extracted information on study design, potential bias, sample characteristics, interventions, and outcomes and rated the strength of overall evidence. Data for each study were extracted by 1 reviewer and confirmed by another. DATA SYNTHESIS: 75 studies (10 randomized, controlled trials [RCTs] and 65 nonrandomized studies) met the inclusion criteria. No RCTs compared radiation therapy with no treatment or no initial treatment. Among the 10 RCTs, 2 compared combinations of radiation therapies, 7 compared doses and fraction sizes of external-beam radiation therapy (EBRT), and 1 compared forms of low-dose rate radiation therapy. Heterogeneous outcomes were analyzed. Overall, moderate-strength evidence consistently showed that a higher EBRT dose was associated with increased rates of long-term biochemical control compared with lower EBRT dose. The body of evidence was rated as insufficient for all other comparisons. LIMITATIONS: Studies inconsistently defined and reported outcomes. Much of the available evidence comes from observational studies with treatment selection biases. CONCLUSION: A lack of high-quality comparative evidence precludes conclusions about the efficacy of radiation treatments compared with no treatments for localized prostate cancer. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Authors: George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin Journal: Can Urol Assoc J Date: 2013 May-Jun Impact factor: 1.862
Authors: Ruth Etzioni; Roman Gulati; Alex Tsodikov; Elisabeth M Wever; David F Penson; Eveline A M Heijnsdijk; Jeffrey Katcher; Gerrit Draisma; Eric J Feuer; Harry J de Koning; Angela B Mariotto Journal: Cancer Date: 2012-05-17 Impact factor: 6.860
Authors: Nishant Gandhi; Aaron T Wild; Sivarajan T Chettiar; Khaled Aziz; Yoshinori Kato; Rajendra P Gajula; Russell D Williams; Jessica A Cades; Anvesh Annadanam; Danny Song; Yonggang Zhang; Russell K Hales; Joseph M Herman; Elwood Armour; Theodore L DeWeese; Edward M Schaeffer; Phuoc T Tran Journal: Cancer Biol Ther Date: 2013-01-28 Impact factor: 4.742
Authors: Tomás Merino; Ignacio F San Francisco; Pablo A Rojas; Piero Bettoli; Alvaro Zúñiga; Pelayo Besa Journal: BMC Cancer Date: 2013-11-08 Impact factor: 4.430
Authors: Sara Alcorn; Amanda J Walker; Nishant Gandhi; Amol Narang; Aaron T Wild; Russell K Hales; Joseph M Herman; Danny Y Song; Theodore L Deweese; Emmanuel S Antonarakis; Phuoc T Tran Journal: Int J Mol Sci Date: 2013-07-16 Impact factor: 5.923
Authors: Tengbin Xiong; Rebecca M Turner; Yinghui Wei; David E Neal; Georgios Lyratzopoulos; Julian P T Higgins Journal: BMJ Open Date: 2014-05-15 Impact factor: 2.692